



Reference List

American Cancer Society. Key statistics for breast cancer. Published May 5, 2025. Accessed November 17, 2025. <https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html>

American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2025. *Diabetes Care*. 2024;48(Suppl 1):S181-S206. doi:10.2337/dc25-S009

André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. *N Engl J Med*. 2019;380(20):1929-1940. doi:10.1056/NEJMoa1813904

Browne IM, André F, Chandarlapaty S, Carey LA, Turner NC. Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer. *Lancet Oncol*. 2024;25(4):e139-e151. doi:10.1016/S1470-2045(23)00676-9

Burstein HJ, DeMichele A, Fallowfield L, Somerfield MR, Henry NL, for the Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels. Endocrine and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer—capivasertib-fulvestrant: ASCO rapid recommendation update. *J Clin Oncol*. 2024;42(12):1450-1453. doi:10.1200/JCO.24.00248

Clark AS, Cobain EF, Dayao Z, Somerfield MR, deMichele A, Henry NL. Biomarkers for systemic therapy in metastatic breast cancer: ASCO guideline update Q and A. *JCO Oncol Pract*. 2022;18(12):830-832. doi:10.1200/OP.22.00506

Fillbrunn M, Signorovitch J, André F, et al. PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials. *BMC Cancer*. 2022;22(1):1002. doi:10.1186/s12885-022-10078-5

Gradishar, WJ, Moran MS, Abraham J, et al. Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer, Version 5.2025. Published October 16, 2025. Accessed November 11, 2025. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

Henry NL, Somerfield MR, Dayao Z, et al. Biomarkers for systemic therapy in metastatic breast cancer: ASCO guideline update. *J Clin Oncol*. 2022;40(27):3205-3221. doi:10.1200/JCO.22.01063

Ibrance. Prescribing information. Pfizer; September 2025. Accessed November 15, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/212436s011lbl.pdf

Itovebi. Prescribing information. Genentech, Inc.; September 2025. Accessed November 15, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219249s002lbl.pdf

Jhaveri KL, Im SA, Saura C, et al. Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer. *N Engl J Med*. 2025;393(2):151-161. doi:10.1056/NEJMoa2501796

LeVee A, Deutsh A, Lindgren ES, et al. New drugs, new toxicities: Side effects of new and emerging breast cancer therapies. *Am Soc Clin Oncol Educ Book*. 2025;45(3):e473384. doi:10.1200/EDBK-25-473384

Liu D, Weintraub MA, Garcia C, et al. Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment. *Cancer Med*. 2022;11(8):1796-1804. doi:10.1002/cam4.4579

PICK THE BEST PATH: OPTIMIZING PIK3CA MUTATION-TARGETED HR+/HER2-PIK3CA-MUTATED THERAPY AND HYPERGLYCEMIA MANAGEMENT



Llombart-Cussac A, Pérez-García JM, Borrego MR, et al. Preventing alpelisib-related hyperglycaemia in HR+/HER2-/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial. *eClinicalMedicine*. 2024;71. doi:10.1016/j.eclinm.2024.102520

Moore HN, Goncalves MD, Johnston AM, et al. Effective strategies for the prevention and mitigation of phosphatidylinositol-3-kinase inhibitor-associated hyperglycemia: optimizing patient care. *Clin Breast Cancer*. 2025;25(1):1-11. doi:10.1016/j.clbc.2024.09.017

Nader-Marta G, Tolaney SM, Mayer EL. Inavolisib-based triplet therapy for PIK3CA-mutated hormone receptor+/HER2- breast cancer: clinical implications and practical considerations. *JCO Oncol Adv*. 2025;(2):e2500041. doi:10.1200/OA-25-00041\

National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts: Female breast cancer subtypes. SEER. Accessed November 17, 2025. <https://seer.cancer.gov/statfacts/html/breast-subtypes.html>

OncoKB. PIK3CA E453K. Updated October 7, 2025. Accessed November 11, 2025. <https://www.oncokb.org/gene/PIK3CA/E453K>

Piqray. Prescribing information. Novartis; January 2024. Accessed November 16, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf

Rugo HS, Lacouture ME, Goncalves MD, Masharani U, Aapro MS, O'Shaughnessy JA. A multidisciplinary approach to optimizing care of patients treated with alpelisib. *Breast Off J Eur Soc Mastology*. 2021;61:156-167. doi:10.1016/j.breast.2021.12.016

Shen S, Chen Y, Carpio A, Chang C, Iyengar NM. Incidence, risk factors, and management of alpelisib-associated hyperglycemia in metastatic breast cancer. *Cancer*. 2023;129(24):3854-3861. doi:10.1002/cncr.34928

Tolaney SM, Punie K, Carey LA, et al. Real-world treatment patterns and outcomes in patients with HR+/HER2-metastatic breast cancer treated with chemotherapy in the United States. *ESMO Open*. 2024;9(9):103691. doi:10.1016/j.esmoop.2024.103691

Truqap. Prescribing information. AstraZeneca Pharmaceuticals LP; November 2025. Accessed January 16, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218197s003lbl.pdf

Tufail M, Hu JJ, Liang J, et al. Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway. *J Transl Med*. 2024;22:15. doi:10.1186/s12967-023-04841-w

Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in hormone receptor-positive advanced breast cancer. *N Engl J Med*. 2023;388(22):2058-2070. doi:10.1056/NEJMoa2214131

Turner NC, Im SA, Saura C, et al. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer. *N Engl J Med*. 2024;391(17):1584-1596. doi:10.1056/NEJMoa2404625